Use of sacubitril/valsartan in non‐compaction cardiomyopathy: a case report

Use of sacubitril/valsartan in non‐compaction cardiomyopathy: a case report

Abstract The use of sacubitril/valsartan significantly reduces death or hospitalization in patients with ejection fraction < 40%. There is no study evaluating this drug effects in non‐compaction cardiomyopathy (NCCM) individuals. The aim of this article is to report a case of a patient with NCCM...

Full description

Bibliographic Details
Main Authors:	Marcely Gimenes Bonatto, Rodrigo Albanez, Vera Maria Cury Salemi, Lídia Zytynski Moura
Format:	Article
Language:	English
Published:	Wiley 2020-06-01
Series:	ESC Heart Failure
Subjects:	Heart failure non‐compaction cardiomyopathy Sacubitril/valsartan Reverse remodelling
Online Access:	https://doi.org/10.1002/ehf2.12713

Similar Items

Effects and clinical implications of sacubitril/valsartan on left ventricular reverse remodeling in patients affected by chronic heart failure: A 24-month follow-up
by: Carla Paolini, et al.
Published: (2021-08-01)

Beneficial Effect of Left Ventricular Remodeling after Early Change of Sacubitril/Valsartan in Patients with Nonischemic Dilated Cardiomyopathy
by: Hyue-Mee Kim, et al.
Published: (2021-04-01)

Effects of sacubitril valsartan on clinical and echocardiographic parameters of outpatients with heart failure and reduced ejection fraction
by: Matteo Landolfo, et al.
Published: (2020-12-01)

Sacubitril/valsartan combination enhanced cardiac glycophagy and prevented the progression of murine diabetic cardiomyopathy
by: Dina Salem Abdelaziz Elshenawy, et al.
Published: (2022-09-01)

Evidence of superiority of sacubitril/valsartan versus angiotensin-converting enzyme inhibitors or angiotensin ii receptor blockers in the heart failure with reduced ejection fraction patient's journey
by: Mauro Gori, et al.
Published: (2021-01-01)

Importance of the ‘area under the curve’ from serial NT‐proBNP measurements during treatment with sacubitril/valsartan
by: Reza Mohebi, et al.
Published: (2023-10-01)

Eligibility for sacubitril–valsartan in patients with acute decompensated heart failure
by: David Carballo, et al.
Published: (2020-06-01)

Efficacy and safety of sacubitril/valsartan vs. valsartan in patients with acute myocardial infarction: A meta-analysis
by: Pei Yang, et al.
Published: (2022-08-01)

What the near Future Holds for Sacubitril/Valsartan: A Summary of Major Ongoing Studies
by: Hisham A. Badreldin, et al.
Published: (2022-02-01)

Reverse remodelling by sacubitril/valsartan predicts the prognosis in heart failure with reduced ejection fraction
by: Mi‐Gil Moon, et al.
Published: (2021-06-01)

Sacubitril/valsartan decreases mortality in the rat model of the isoprenaline‐induced takotsubo‐like syndrome
by: Anwar Ali, et al.
Published: (2021-10-01)

Cooling down with Entresto. Can sacubitril/valsartan combination enhance browning more than coldness?
by: Marina Nikolic, et al.
Published: (2022-11-01)

Sacubitril/valsartan in patients listed for heart transplantation: effect on physical frailty
by: Francesco Cacciatore, et al.
Published: (2020-04-01)

Sacubitril/Valsartan Ameliorates Crizotinib-Induced Cardiotoxicity in Mice
by: Lijun Cheng, et al.
Published: (2023-07-01)

A Simple Score to Identify Super-Responders to Sacubitril/Valsartan in Ambulatory Patients With Heart Failure
by: Carles Moliner-Abós, et al.
Published: (2021-02-01)

First signs of reverse cardiac remodeling following one-month, low dose add-on sacubitril-valsartan therapy in patients with advanced systolic heart failure
by: Wioletta Sacharczuk, et al.
Published: (2022-03-01)

Combination of ivabradine and sacubitril/valsartan in patients with heart failure and reduced ejection fraction
by: Ying‐Hsiang Lee, et al.
Published: (2021-04-01)

Dose titration of sacubitril/valsartan for heart failure with reduced ejection fraction: a real‐world study
by: Chen Wang, et al.
Published: (2023-06-01)

Deformation Imaging by Strain in Chronic Heart Failure Over Sacubitril‐Valsartan: A Multicenter Echocardiographic Registry
by: Giulia Elena Mandoli, et al.
Published: (2023-04-01)

The effects of sacubitril/valsartan and ramipril on the male fertility in hypertensive rats
by: Duygun Altıntaş Aykan, et al.
Published: (2020-10-01)

Sacubitril/Valsartan and Ivabradine Attenuate Left Ventricular Remodelling and Dysfunction in Spontaneously Hypertensive Rats: Different Interactions with the Renin–Angiotensin–Aldosterone System
by: Fedor Simko, et al.
Published: (2022-07-01)

Comparative Study of the Efficacy and Safety of Sacubitril/Valsartan and Dapagliflozin in the Treatment of Dilated Cardiomyopathy with Low Blood Pressure
by: ZHANG Yong, CAI Xiang, NING Feifei, LIANG Xiao, GUO Ning
Published: (2023-08-01)

Sacubitril/valsartan attenuates atrial structural remodelling in atrial fibrillation patients
by: Liu Yang, et al.
Published: (2022-08-01)

The Effect of Sacubitril/Valsartan on Device Detected Arrhythmias and Electrical Parameters among Dilated Cardiomyopathy Patients with Reduced Ejection Fraction and Implantable Cardioverter Defibrillator
by: Vincenzo Russo, et al.
Published: (2020-04-01)

Impact of Sacubitril/Valsartan on Circulating microRNA in Patients with Heart Failure
by: Maura Brioschi, et al.
Published: (2023-03-01)

Sacubitril/Valsartan for Heart Failure: Exciting Times but Are Doctors Informed and Ready?
by: Prithwish Banerjee
Published: (2017-01-01)

Implementation of sacubitril/valsartan in Sweden: clinical characteristics, titration patterns, and determinants
by: Michael Fu, et al.
Published: (2020-12-01)

Renin profiling predicts neurohormonal response to sacubitril/valsartan
by: Giuseppe Vergaro, et al.
Published: (2021-02-01)

The Efficacy and Safety of Sacubitril/Valsartan Compared to Valsartan in Patients with Heart Failure and Mildly Reduced and Preserved Ejection Fractions: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Sharath Kommu, et al.
Published: (2024-03-01)

Use of Sacubitril/valsartan in patients with cardio toxicity and heart failure due to chemotherapy
by: Vanesa Gregorietti, et al.
Published: (2020-11-01)

A Rare Adverse Event of Rhabdomyolysis Caused by Sacubitril/Valsartan
by: Prashanth Rawla, et al.
Published: (2019-05-01)

Mechanistic Efficacy of Sacubitril/Valsartan in Ischemic Versus Nonischemic Heart Failure
by: Reza Mohebi, et al.
Published: (2023-04-01)

Effect of Emergency Percutaneous Coronary Intervention Combined with Sacubitril and Valsartan on the Cardiac Prognosis in Patients with Acute Myocardial Infarction
by: Fan H, et al.
Published: (2023-02-01)

Left ventricular output indices and sacubitril/valsartan titration: role of stroke volume index
by: Paolo Tolomeo, et al.
Published: (2022-06-01)

Effectiveness of sacubitril–valsartan in cancer patients with heart failure
by: Ana Martín‐Garcia, et al.
Published: (2020-04-01)

Dilated cardiomyopathy and aldosteronoma: a causal link?
by: Jiyu Zhang, et al.
Published: (2020-02-01)

Comparative and Combinatorial Effects of Resveratrol and Sacubitril/Valsartan alongside Valsartan on Cardiac Remodeling and Dysfunction in MI-Induced Rats
by: Pema Raj, et al.
Published: (2021-08-01)

Efficacy and safety of sacubitril‐valsartan in heart failure: a meta‐analysis of randomized controlled trials
by: Hongzhou Zhang, et al.
Published: (2020-12-01)

Molecular mechanisms of sacubitril/valsartan in cardiac remodeling
by: Nor Hidayah Mustafa, et al.
Published: (2022-08-01)

Cardiac Reverse Remodelling by 2D and 3D Echocardiography in Heart Failure Patients Treated with Sacubitril/Valsartan
by: Valentina Mantegazza, et al.
Published: (2021-10-01)